Anupan Rasayan projects 20-25% revenue growth in FY24 on demand uptick in second half

Anupam Rasayan, a prominent player in the chemical and speciality chemical industry, is making strategic moves to bolster its position in the pharmaceutical sector. The pharma business contribution to revenue has now increased to 4% from 2% last year.

Discussing the company's growth trajectory, Vishal Thakkar, Deputy CFO of Anupam Rasayan, stated that demand growth had been pushed to the second half of the year.

For FY24, the company expects revenue growth to range between 20% and 25%. On EBITDA (earnings before interest, tax, depreciation, and amortisation) margin, the company has a guidance of 26-28%.

The company envisions substantial growth opportunities in the pharma and chlorination segments. It anticipates that the pharma division will make a considerable leap by the end of this year. Over the next 3 to 5 years, the pharma sector is likely to contribute around 20% of its total revenue.

| Anupam Rasayan inks pact with 3xper Innoventure for targeted and new-age pharma molecules

In its most recent financial report, Anupam Rasayan disclosed a marginal increase in profit for the second quarter. The company's net profit experienced a year-on-year rise of 1.8%, reaching ₹48.7 crore in the quarter ending in September (Q2FY24).

Anupam Rasayan, headquartered in Gujarat, has garnered significant recognition in the chemical industry, boasting a market capitalisation of approximately ₹9,776 crore.

For more details, watch the accompanying video